Welcome to our dedicated page for Kala Pharmaceuticals SEC filings (Ticker: KALA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical-stage biotech filings can feel impenetrable—especially when they involve stem-cell secretomes, nanoparticle delivery science, and pages of trial data. Kala Pharmaceuticals SEC filings explained simply is exactly what most investors need when the latest 300-page document lands on EDGAR. Whether you are hunting for safety signals around KPI-012 or trying to gauge cash runway before the next Phase 2 read-out, our AI breaks down the jargon and highlights what really moves the share price.
Here you will find every form, from a Kala Pharmaceuticals annual report 10-K simplified to a Kala Pharmaceuticals quarterly earnings report 10-Q filing, plus Kala Pharmaceuticals 8-K material events explained within minutes of posting. Stock Titan’s AI-powered summaries show where milestone payments hit the income statement, flag trial-halt clauses hidden in footnotes, and answer real questions like “understanding Kala Pharmaceuticals SEC documents with AI” or “Kala Pharmaceuticals earnings report filing analysis” without scrolling line-by-line.
Need real-time visibility into management’s moves? Monitor Kala Pharmaceuticals insider trading Form 4 transactions and receive Kala Pharmaceuticals Form 4 insider transactions real-time alerts that spotlight option exercises and open-market buys. The page also connects each Kala Pharmaceuticals proxy statement executive compensation detail to dilution scenarios so you can calculate true cost of equity. Use our platform to track Kala Pharmaceuticals executive stock transactions Form 4, compare R&D trends across quarters, and export risk-factor lists for your model. Complex filings, clear insights—so you invest with confidence.
KALA BIO (Nasdaq: KALA) Q2 2025 10-Q highlights
- No commercial revenue after 2022 business sale; the model is now fully R&D-focused on lead candidate KPI-012 for persistent corneal epithelial defects (PCED).
- Losses narrowed modestly. Six-month net loss was $20.1 m vs. $21.4 m YoY; quarterly loss was $11.2 m.
- Cash burn improved: operating cash outflow $16.6 m vs. $20.1 m YoY. However, cash & equivalents fell to $31.9 m from $51.2 m at 12/31/24.
- Runway & going-concern. Management projects liquidity into 1Q 2026 but discloses “substantial doubt” about continuing as a going concern without additional capital.
- Balance sheet deterioration. Shareholders’ equity turned negative (-$3.2 m) from +$12.3 m; accumulated deficit reached $688 m.
- Expenses. 1H 25 R&D $12.3 m (+5% YoY); G&A $9.2 m (-5%). Grant income of $2.9 m from CIRM partially offsets costs.
- Debt. Total Oxford loan balance $28.3 m (current $9.5 m); $2.5 m principal repaid YTD. Compliance depends on maintaining Nasdaq listing.
- Milestone potential. Up to $325 m of sales-based payments from Alcon remain possible but timing uncertain; $4.8 m in Combangio contingent liabilities remain on balance sheet.
- Share count 7.0 m common as of 8/7/25; Series E–I convertible preferred outstanding but carry no dividend or liquidation preference.
Management continues Phase 2b CHASE trial for KPI-012; additional capital raises, partnerships or cost cuts are being evaluated.
KALA BIO announced that it has released its quarterly results for the period ending June 30, 2025 and provided a general business and corporate update. The company has furnished a press release as Exhibit 99.1 to this Form 8-K so investors can read the full update. The filing notes that the information is being furnished (not "filed") under the Exchange Act and therefore is for disclosure rather than subject to certain filing liabilities.
KALA Bio (Nasdaq: KALA) has finished enrolling all 79 patients in its CHASE Phase 2b trial of KPI-012, a human mesenchymal stem-cell secretome therapy for persistent corneal epithelial defect (PCED). The multicenter, randomized, double-masked study is comparing two doses (3 U/mL and 1 U/mL) of KPI-012 to vehicle, dosed topically four times daily for 56 days across 37 sites in the United States and Latin America.
Key trial design highlights
- Primary endpoint: complete healing of PCED assessed via fluorescein staining reviewed by a masked central reading center.
- Next catalyst: topline safety and efficacy data expected in Q3 2025.
- Regulatory pathway: management believes positive results could allow CHASE to serve as the first of two pivotal trials supporting a Biologics License Application (BLA) with the U.S. FDA.
The 8-K filing contains forward-looking statements outlining typical clinical, regulatory and market risks but provides no financial metrics or changes to guidance.
Investment view: Completion of enrollment de-risks timeline execution and sets a near-term data read-out, yet clinical success and regulatory approval remain the primary value-drivers.
Kala Bio Chief Business Officer Darius Kharabi reported a sale of 4,511 shares of common stock on June 24, 2025, at a weighted average price of $4.01 per share (ranging from $3.87 to $4.12). The transaction was executed under a pre-established 10b5-1 trading plan from November 16, 2021.
Key details of the transaction:
- The sale was specifically made to cover tax withholding obligations related to RSU vesting from a June 22, 2023 grant
- Following the transaction, Kharabi maintains beneficial ownership of 62,566 shares, including 28,878 unvested RSUs
- The transaction was executed as a direct ownership sale
- The Form 4 was filed through an attorney-in-fact on June 26, 2025
This planned sale under Rule 10b5-1 demonstrates standard executive equity management for tax obligations rather than a discretionary trading decision.
Kala Bio CFO Mary Reumuth reported a sale of 3,631 shares of common stock on June 24, 2025, at a weighted average price of $4.01 per share (range: $3.87-$4.12). The transaction was executed under a pre-established 10b5-1 trading plan from November 9, 2020.
Key details of the transaction:
- The sale was specifically made to cover tax withholding obligations related to RSU vesting from a June 22, 2023 grant
- Following the transaction, Reumuth maintains beneficial ownership of 62,100 shares, including 28,906 unvested RSUs
- The transaction was reported via Form 4 within the required filing deadline
This planned sale under Rule 10b5-1 demonstrates standard executive equity management practices for tax obligations and does not indicate a significant change in the CFO's overall position in the company.
Kala Bio insider Todd Bazemore, serving as Interim CEO, President and COO, reported a transaction on June 24, 2025 involving the sale of 4,058 shares of common stock at a weighted average price of $4.01 per share (range: $3.87-$4.12).
Key details of the transaction:
- Sale was executed under a 10b5-1 trading plan established on November 10, 2020
- Purpose: Cover tax withholding obligations related to RSU vesting from June 22, 2023 grant
- Post-transaction holdings: 83,699 shares (including 35,732 unvested RSUs) held directly
- Additional indirect ownership: 1 share held by son
The transaction was reported via Form 4 filing, signed by Mary Reumuth as attorney-in-fact on June 26, 2025, complying with SEC disclosure requirements for insider trading activity.
Kala Bio insider trading activity reported: Head of Research and Development and Chief Medical Officer Romulus K. Brazzell sold 5,251 shares of common stock on June 24, 2025, at a weighted average price of $4.01 per share (range: $3.87-$4.12).
Key details:
- Sale executed under a 10b5-1 trading plan established November 9, 2020
- Transaction purpose: Cover tax withholding obligations from RSU vesting granted June 22, 2023
- Post-transaction holdings: 82,698 shares, including 35,952 unvested RSUs
- Transaction form: Direct ownership
The sale was made in compliance with SEC regulations and followed a pre-established trading plan, indicating a routine transaction rather than a strategic investment decision.
Kala Bio (NASDAQ:KALA) filed a routine Form 4 reporting that director Mark T. Iwicki sold 13,227 common shares on June 24 2025 at a weighted-average price of $4.01 per share, generating roughly $53 000 in gross proceeds.
The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 9 2020 to cover tax-withholding obligations related to the vesting of restricted stock units (RSUs) granted on June 22 2023.
After the sale, Iwicki retains 258 433 shares, including 103 540 unvested RSUs, meaning the disposition represents slightly under 5 % of his prior beneficial ownership. No changes to company operations, strategy, or financial condition are disclosed.
FAQ
What is the current stock price of Kala Pharmaceuticals (KALA)?
What is the market cap of Kala Pharmaceuticals (KALA)?
